Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)

Bio­gen makes $1.15B buy for ARCH's HI-Bio to ex­pand im­munol­o­gy pipeline

Bio­gen is fur­ther ex­pand­ing be­yond its neu­ro­science roots and dip­ping more in­to im­munol­o­gy with a $1.15 bil­lion up­front ac­qui­si­tion of Hu­man Im­munol­o­gy Bio­sciences, or HI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.